Northwest Biotherapeutics Enters Material Definitive Agreement
Ticker: NWBO · Form: 8-K · Filed: 2025-10-31T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, financial-obligation
Related Tickers: NWBO
TL;DR
NWBO just signed a big deal creating a financial obligation. Keep an eye on this.
AI Summary
On October 27, 2025, Northwest Biotherapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware with its principal executive offices in Bethesda, Maryland, filed this Form 8-K to report this event.
Why It Matters
This filing indicates Northwest Biotherapeutics has entered into a significant agreement that creates a financial obligation, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial risks and operational complexities for a company.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- October 27, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 4800 Montgomery Lane, Suite 800 Bethesda, Maryland 20814 (address) — Principal Executive Offices
- (240) 497-9024 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did Northwest Biotherapeutics, Inc. enter into?
The filing states that Northwest Biotherapeutics, Inc. entered into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant. Specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 27, 2025.
What is the principal executive office address for Northwest Biotherapeutics, Inc.?
The principal executive offices of Northwest Biotherapeutics, Inc. are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the IRS Employer Identification Number (EIN) for Northwest Biotherapeutics, Inc.?
The IRS Employer Identification Number (EIN) for Northwest Biotherapeutics, Inc. is 94-3306718.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-31 12:29:10
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
- $5,505,000 — al, LLC (the "Holder") in the amount of $5,505,000. The Loan Agreement has a maturity of 2
Filing Documents
- tm2529815d1_8k.htm (8-K) — 24KB
- 0001104659-25-104812.txt ( ) — 183KB
- nwbo-20251027_lab.xml (EX-101.LAB) — 33KB
- nwbo-20251027_pre.xml (EX-101.PRE) — 22KB
- nwbo-20251027.xsd (EX-101.SCH) — 3KB
- tm2529815d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry into a Material Definitive Agreement. Loan Entered Into On October 27, 2025, Northwest Biotherapeutics, Inc. (the "Company") entered into a Commercial Loan Agreement and Note (collectively, the "Loan Agreement") with Streeterville Capital, LLC (the "Holder") in the amount of $5,505,000. The Loan Agreement has a maturity of 22 months. There are no repayments for the first 8 months. Repayments will begin June 26, 2026. Following June 26, 2026, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company's election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration. The funds will be used for the Company's ongoing business operations.
03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: October 31, 2025 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman